The immuno-oncology drug market exceeded ₩400 billion in annual sales only 7 years since its debut in Korea. With Keytruda in the lead making over ₩200 billion in sales, the latecomers Tecentriq and Imfinzi are chasing the lead with its rapid growth.

According to the market research institution IQVIA on the 4th, the total immuno-oncology treatment that consists of 6 immuno-oncology drugs in Korea has made ₩407 billion last year, a ₩285.6 billion increase and a 42.5% YoY increase from the previous year. This record was made in 7 years since the first immuno-oncology drug Yervoy (Ipilimumab) was approved in December 2014.

The release of Yervoy marked the sta